Drug Profile
Research programme: bacterial and viral infection therapeutics - Pfizer/GlaxoSmithKline
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals
- Developer Anacor Pharmaceuticals; GSK
- Class Organic boron compounds; Small molecules
- Mechanism of Action Amino acyl tRNA synthetase inhibitors; Hepatitis C protease inhibitors; Leucyl-tRNA synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Gram-negative infections; Hepatitis C; Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (PO)